Clinical Trial: Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies
Study Status: Completed
Recruit Status: RECRUITING
Condition: Chronic Lymphocytic Leukemia
Study Type: INTERVENTIONAL
Official Title: A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies
Brief Summary:
Background:About 23,000 people die from B-cell cancers in the US each year.These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells.These cancers are difficult to treat, and the therapies used can have bad side effects.Researchers want to try a new type of treatment.This new treatment uses a patient s own immune cells (T cells) that are modified to carry genes (chimeric antigen receptor, or CAR T cells) to kill cancer cells.Objective:To test a treatment using CAR T cells…
Read more